Skip to main content
. 2022 May 7;32(4):334–341. doi: 10.4103/ijn.ijn_340_21

Table 3.

Profile of individual parameters of SGNA at baseline and follow-up

SGNA parameters (n,%) Baseline (n=41) 1st follow-up (n=38) 2nd follow-up (n=30)
Height for age
 Normal 16 (39.0) 15 (39.4) 10 (33.3)
 Moderately less 14 (34.1) 13 (34.2) 13 (43.3)
 Severely less 11 (26.8) 10 (26.3) 7 (23.3)
Weight for age
 Normal 7 (17.0) 10 (26.3) 5 (16.6)
 Moderately less 14 (34.1) 13 (34.2) 14 (46.6)
 Severely less 20 (48.7) 15 (39.4) 11 (36.6)
Change in body weight
 No change 24 (58.5) 23 (60.5) 20 (64.5)
 Improved 17 (41.4) 15 (39.4) 11 (35.4)
 Worsened 0 0 0
Diet intake
 Adequate 23 (56.1) 22 (57.8) 18 (60)
 Hypocaloric 17 (41.4) 16 (42.1) 12 (40)
 Starvation 1 (2.4) 0 0
GI symptoms
 None 39 (95.1) 37 (97.3) 29 (96.6)
 Not daily 2 (4.8) 1 (2.6) 1 (3.3)
 Daily 0 0 0
Functional capacity
 Energetic 16 (39.0) 12 (31.5) 15 (50)
 Restricted 24 (58.5) 25 (65.7) 14 (46.6)
 Little or no play 1 (2.4) 1 (2.6) 1 (3.3)
Metabolic stress
 None 5 (12.2) 7 (18.4) 5 (16.6)
 Moderate 36 (87.8) 30 (78.9) 25 (83.3)
 Severe 0 1 (2.6) 0
Loss of subcutaneous fat
 Normal 19 (46.3) 17 (44.7) 11 (36.6)
 Moderate 13 (31.7) 12 (31.5) 12 (40)
 Severe 9 (21.9) 9 (23.6) 7 (23.3)
Muscle Wasting
 None 13 (31.7) 12 (31.5) 5 (16.6)
 Moderate 18 (43.9) 14 (36.8) 15 (50)
 Severe 10 (24.3) 12 (31.5) 10 (33.3)
Oedema
 Normal 13 (31.7) 10 (26.3) 6 (20)
 Moderate 27 (65.8) 28 (73.6) 23 (76.6)
 Severe 1 (2.4) 0 1 (3.3)